Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells

Acta Biochimica et Biophysica Sinica

Volumn 42, Issue 2, 2010, Pages 137-144

  Yang, Deyong ^a   Song, Xishuang ^a   Zhang, Jianing ^a   Ye, Lin ^a   Wang, Shujing ^a   Che, Xiangyu ^a   Wang, Jianbo ^a   Zhang, Zhiwei ^a   Wang, Lina ^a   Shi, Wei ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Bladder cancer; Livin; Multi targeted therapy; Survivin; XIAP

Indexed keywords

BIRC5 PROTEIN, HUMAN; BIRC7 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA; TUMOR PROTEIN; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

ARTICLE; BLADDER TUMOR; DOWN REGULATION; DRUG EFFECT; GENE SILENCING; GENE THERAPY; GENETICS; HUMAN; METABOLISM; METHODOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TUMOR; DOWN-REGULATION; GENE SILENCING; GENE THERAPY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; RNA, SMALL INTERFERING; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 76349122706     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmp118     Document Type: Article

References (28)

1. Lowe SW and Lin AW. Apoptosis in cancer. Carcinogenesis 2000, 21: 485-495.
2. Kasibhatla S and Tseng B. Why target apoptosis in cancer treatment? Mol Cancer Ther 2003, 2: 573-580.
3. Vaux DL and Silke J. Mammalian mitochondrial IAP binding proteins. Biochem Biophys Res Commun 2003, 304: 499-504.
4. Wei Y, Fan T and Yu M. Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin 2008, 40: 278-288.
5. Srinivasula SM and Ashwell JD. IAPs: what's in a name? Mol Cell 2008, 30: 123-135.
6. Dubrez-Daloz L, Dupoux A and Cartier J. IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 2008, 7: 1036-1046.
7. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S and Korneluk RG. IAP-targeted therapies for cancer. Oncogene 2008, 27: 6252-6275.
8. Kasof GM and Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001, 276: 3238-3246.
9. Sah NK, Khan Z, Khan GJ and Bisen PS. Structural, functional and therapeutic biology of survivin. Cancer Lett 2006, 244: 164-171.
10. Eckelman BP, Salvesen GS and Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006, 7: 988-994.
11. Pepita GB, Avelina T and Ricardo PT. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 2009, 9: 320-340.
12. Nachmias B, Ashhab Y and Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 2004, 14: 231-243.
13. Liu B, Han M, Wen JK and Wang L. Livin/ML-IAP as a new target for cancer treatment. Cancer Lett 2007, 250: 168-176.
14. Dean EJ, Ranson M, Blackhall F and Dive C. X-linked inhibitor of apoptosis protein as a therapeutic target. Expert Opin Ther Targets 2007, 11: 1459-1471.
15. Pennati M, Folini M and Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008, 12: 463-476.
16. Gimenez-Bonafe P, Tortosa A and Perez-Tomas R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 2009, 9: 320-340.
17. Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004, 53: 153-159.
18. Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B and Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 2004, 64: 3006-3008.
19. Leung RK and Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 2005, 107: 222-239.
20. Jackson AL and Linsley PS. Noise amidst the silence: off-target effects of siRNAs? Trends Genet 2004, 20: 521-524.
21. Chen DJ and Huerta S. Smac mimetics as new cancer therapeutics. Anticancer Drugs 2009, 20: 646-658.
22. Ma L, Huang Y, Song Z, Feng S, Tian X, Du W and Qiu X, et al. Livin promotes Smac/DIABLO degradation by ubiquitin-proteasome pathway. Cell Death Differ 2006, 13: 2079-2088.
23. Morizane Y, Honda R, Fukami K and Yasuda H. X-linked inhibitor of apoptosis functions as ubiquitin ligase toward mature caspase-9 and cytosolic Smac/DIABLO. J Biochem 2005, 137: 125-132.
24. Obiol-Pardo C, Granadino-Roldan JM and Rubio-Martinez J. Protein- protein recognition as a first step towards the inhibition of XIAP and Survivin anti-apoptotic proteins. J Mol Recognit 2008, 21: 190-204.
25. Scott FL, Denault JB, Riedl SJ, Shin H, Renatus M and Salvesen GS. XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J 2005, 24: 645-655.
26. McNeish IA, Lopes R, Bell SJ, McKay TR, Fernandez M, Lockley M and Wheatley SP, et al. Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. Exp Cell Res 2005, 302: 69-82.
27. Dorsett Y and Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 2004, 3: 318-329.
28. Feril LB, Jr. Ultrasound-mediated gene transfection. Methods Mol Biol 2009, 542: 179-194.